UBS Group
ARGS

UBS Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

UBS Group’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,354
Closed -$8K – 8671
2018
Q1 		$8K Buy
9,354
+9,346
+116,825% +$17.5K ﹤0.01% 7058
2017
Q4 		$0 Sell
8
-4,692
-100% -$15.7K ﹤0.01% 8499
2017
Q3 		$17K Buy
4,700
+4,482
+2,056% +$21.5K ﹤0.01% 6590
2017
Q2 		$1K Buy
218
+158
+263% +$1.34K ﹤0.01% 7601
2017
Q1 		$1K Sell
60
-247
-80% -$15.6K ﹤0.01% 7571
2016
Q4 		$30K Buy
307
+72
+31% +$6.74K ﹤0.01% 6253
2016
Q3 		$23K Sell
235
-277
-54% -$28.9K ﹤0.01% 6211
2016
Q2 		$63K Buy
512
+412
+412% +$55K ﹤0.01% 5354
2016
Q1 		$13K Buy
+100
New +$8.09K ﹤0.01% 6524
2015
Q4 		– Sell
-137
Closed -$13K – 8996
2015
Q3 		$13K Buy
+137
New +$16.2K ﹤0.01% 7120
2015
Q2 		– Sell
-87
Closed -$15K – 9356
2015
Q1 		$15K Buy
+87
New +$15.1K ﹤0.01% 7328

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ARGS Position: Q2 2018 in Review

UBS Group sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 9,354 shares — an estimated $8K sold.

UBS Group first reported a position in ARGS in Q1 2015 and held it in 11 quarters. The position peaked at $63K in Q2 2016. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

  • UBS Group reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • UBS Group sold 9,354 Argos Therapeutics, Inc. shares in Q2 2018, an estimated $8K.
  • UBS Group first reported a position in Argos Therapeutics, Inc. in Q1 2015 and held it in 11 quarters.
  • UBS Group's Argos Therapeutics, Inc. position peaked at $63K in Q2 2016.
  • 4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.